After some health authorities in some countries suspended the use of its Covid-19 vaccine over blood clotting issues, AstraZeneca Plc has said that a review of safety data of people vaccinated with its Covid-19 vaccine has shown no evidence of an increased risk of blood clots.
“A careful review of all available safety data of more than 17 million people vaccinated in the European Union and the UK with Covid-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country,” the company said.
Authorities in Ireland, Denmark, Norway, and Iceland have suspended the use of the vaccine over clotting issues, while Austria stopped using a batch of AstraZeneca shots last week while investigating death from blood clotting.
Meanwhile, the European Medicines Agency has said there is no indication that the blood clottings were caused by the vaccination. This was echoed by the World Health Organization on Friday.
The AstraZeneca vaccine, developed in collaboration with Oxford University, has been authorized for use in the European Union and many other countries.
“A careful review of all available safety data of more than 17 million people vaccinated in the European Union and the UK with Covid-19 Vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country,” the company said.
Authorities in Ireland, Denmark, Norway, and Iceland have suspended the use of the vaccine over clotting issues, while Austria stopped using a batch of AstraZeneca shots last week while investigating death from blood clotting.
Meanwhile, the European Medicines Agency has said there is no indication that the blood clottings were caused by the vaccination. This was echoed by the World Health Organization on Friday.
The AstraZeneca vaccine, developed in collaboration with Oxford University, has been authorized for use in the European Union and many other countries.
